There are several ways to mobilize hematopoietic stem cells for autologous and allogeneic hematopoietic stem cell transplant by manipulating the bone marrow microenvironment. Granulocyte colony-stimulating factor (G-CSF) and chemotherapy have been commonly used to mobilize stem cells, but several new agents, such as the CXCR4 inhibitor plerixafor, inhibit stromal-stem cell interactions to improve stem cell yield. The minimum threshold for engraftment is 2 × 106 CD34+ cells/kg, but it has been shown that higher CD34+ stem cell dose, such as 5 × 106 CD34+ cells/kg, is associated with improved survival. Efforts to increase stem cell yield remain important to improve outcomes.

Original languageEnglish
Pages (from-to)519-523
Number of pages5
JournalBest Practice and Research: Clinical Haematology
Issue number4
StatePublished - Dec 2010


  • Allogeneic
  • Autologous
  • G-CSF
  • GM-CSF
  • Plerixafor
  • Stem cell mobilization


Dive into the research topics of 'Can every patient be mobilized?'. Together they form a unique fingerprint.

Cite this